Novavax’s prototype vaccine effective against omicron variants, study finds

In a late-stage trial, Novavax’s prototype COVID-19 vaccine increased neutralizing antibody titers up to 34 times higher than primary vaccination among adults, with a “significant boost” against omicron variants and subvariants BA.1, BA.2 and BA.5. 

Advertisement

In the same study, one booster shot increased neutralizing titers 2.7-fold among teenagers between 12 and 17 years old, Novavax said Oct. 12. 

The vaccine-maker, which began distributing its COVID-19 vaccine after gaining the FDA and CDC’s authorization in July, said the prototype booster doses were well tolerated and side effects were mainly mild to moderate.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.